Abstract 10341: Prevalence and Factors Associated With Statin Use Among a Nationally Representative Sample of US Adults - National Health and Nutrition Examination Survey, 2011-2012

Abstract

Background: The 2013 AHA/ACC guidelines recommend the use of statins for adults ≤75 years who have clinical ASCVD (IA) and for primary prevention among persons aged 40 – 75 with diabetes mellitus and LDL btw 70 - 189mg/dl (IA). The aim of this study was to estimate the prevalence and likelihood of statin use among selected statin benefit groups. Methods: Using data from the National Health and Nutrition Examination Survey (NHANES) for the 2011 - 2012 cycle, we examined 5,319 adults aged 20 years and older. We estimated weighted frequencies and proportions with confidence intervals for the entire sample and for persons with diabetes and LDL ≥70 or a diagnosis of dyslipidemia, denoted statin benefit group 1 (SBG1) and for persons with history of ASCVD, statin benefit group 2 (SBG2). We constructed a multivariable logistic regression model to estimate the odds of statin use among persons in SBG1. All analyses were conducted using SAS survey procedures for complex sample data and evaluated at α=0.05. Results: Among persons in SBG1 (mean age: 61yrs), 59.5% (95% CI: 53.0 – 66.1), an estimated 10.6 million persons and 63.5% (95% CI: 55.6 – 71.4) of persons in SBG2 (mean age: 65yrs), an estimated 10.8 million persons were on a statin. A sub-population analysis among persons aged 40 – 75 showed statin use to be 58.8% (95% CI: 51.5 – 66.1) for persons in SBG1. Overall, an estimated 38.6 million Americans are on a statin, an increase from 24 million in 2003-2004. In adjusted models, uninsured persons and Hispanics compared to Whites were less likely to be on a statin. Conclusion: The prevalence of statin use among US adults has tripled since 1999-2000. However racial disparities and lack of insurance remain a barrier to statin use. Our study provides a baseline estimate of statin use in the noninstitutionalized civilian adult population just prior to the introduction of the new guidelines and provides a reference for evaluating the impact of the 2013 guidelines on statin utilization.